Molecular science
Semaglutide vs. Tirzepatide vs. Retatrutide
Semaglutide activates the glucagon-like peptide-1 receptor (GLP-1R). Tirzepatide also activates the glucose-dependent insulinotropic polypeptide receptor (GIPR); retatrutide adds the glucagon receptor (GCGR). Each is a single modified peptide. Their one-, two- and three-target profiles are a starting point for comparing their chemistry and laboratory activity.
The clearest difference: receptor targets
A receptor is a protein that receives a molecular signal. An agonist binds to a receptor and promotes its activation. “Single,” “dual” and “triple” count the receptor types one molecule can activate. They do not tell you how strongly it acts at each target. [1] [2] [3] [7]
Glucagon-like peptide-1 and glucagon are separate peptide signals with distinct receptors. Their similar names do not make the targets interchangeable. [3] [7]
The three molecules, side by side
All three have an amino-acid backbone and a lipid component attached through a chemical linker. A building block within the backbone is called a residue. The table counts positions from the first residue of each chain. [1] [3] [5]
Tirzepatide and retatrutide have the same chain length, but their sequences differ. The position of the lipid branch differs too. Matching a residue count or a lipid length is only a partial description of a molecule. [2] [3]
| Feature | Semaglutide | Tirzepatide | Retatrutide |
|---|---|---|---|
| Receptor targets | GLP-1R. [1] | GLP-1R and GIPR. [2] [5] | GLP-1R, GIPR and GCGR. [3] [4] |
| Backbone length | 31 residues. [1] | 39 residues. [2] [5] | 39 residues. [3] |
| Lipid component | 18-carbon fatty diacid. [6] | 20-carbon fatty diacid. [5] | 20-carbon fatty diacid. [3] |
| Branch attachment | Lysine at chain position 20. [4] [6] | Lysine at chain position 20. [4] [5] | Lysine at chain position 17. [3] [4] |
| First residue | Histidine. [1] | Tyrosine. [2] | Tyrosine. [3] |
Receptor targets
Backbone length
Lipid component
Branch attachment
First residue
Why semaglutide’s attachment site is also called Lys26
Semaglutide papers often retain the numbering of glucagon-like peptide-1 (GLP-1)(7–37), so the first residue is numbered 7. Conventional Lys26 is therefore the twentieth residue along this 31-residue chain. The comparison table uses chain positions consistently across all three molecules. [6]
Lys is the abbreviation for lysine. Before comparing two labeled structures, check where each numbering system starts.
What they share: a route into cellular signaling
These receptors span the cell membrane and belong to the G protein-coupled receptor family. When activated, they can engage the stimulatory G protein (Gs) inside the cell. Gs stimulates adenylyl cyclase, an enzyme that converts adenosine triphosphate (ATP) into cyclic adenosine monophosphate (cAMP). This small molecule carries the signal onward. [8] [9]
Measuring cAMP is one way to study receptor activation. It captures part of the response; what follows depends on the cell’s proteins and signaling machinery. A shared signaling route does not guarantee the same response from each molecule. [8] [9]
What the lipid branch changes
Lipid attachment can support reversible binding to albumin, a soluble protein. Albumin binding is a different interaction from receptor activation, and albumin in an assay can affect the peptide available to interact with receptors. [5] [6]
The branch can also influence receptor activity. Sun and colleagues compared tirzepatide with a version lacking its lipid branch. In their GLP-1R assays using engineered cells, removing the branch increased cAMP potency while binding affinity changed little. That result concerns a modified tirzepatide molecule in the tested system. [5]
An 18-carbon versus a 20-carbon branch therefore cannot, by itself, predict a response. The peptide sequence, linker, attachment site and experimental conditions also matter.
Three laboratory examples, three different questions
These in vitro experiments used engineered cells or isolated cell membranes. Each study tested a different question with its own controls, so the results cannot rank the three peptides. Read across each row to connect the model, comparison and finding. [4] [6] [7]
| Study and model | What was compared? | What was observed? |
|---|---|---|
| Semaglutide — Lau et al.; receptor-bearing membranes isolated from engineered cells. | GLP-1R binding under low- and high-albumin conditions. | More semaglutide was needed to displace the reference ligand at higher albumin. The assay conditions changed the binding result. [6] |
| Tirzepatide — Willard et al.; cells with tagged receptors. | Tirzepatide versus glucagon-like peptide-1 (GLP-1), measuring receptor movement into the cell. | Tirzepatide produced less GLP-1R internalization in this assay. This measures receptor location, rather than cAMP production. [7] |
| Retatrutide — Li et al.; engineered cells expressing the glucagon receptor. | Changing one amino acid in the receptor (E362A), versus the unaltered receptor. | The alteration reduced retatrutide’s cAMP potency. The receptor changed; the peptide remained the same. [4] |
Semaglutide — Lau et al.; receptor-bearing membranes isolated from engineered cells.
- What was compared?
- GLP-1R binding under low- and high-albumin conditions.
- What was observed?
- More semaglutide was needed to displace the reference ligand at higher albumin. The assay conditions changed the binding result. [6]
Tirzepatide — Willard et al.; cells with tagged receptors.
- What was compared?
- Tirzepatide versus glucagon-like peptide-1 (GLP-1), measuring receptor movement into the cell.
- What was observed?
- Tirzepatide produced less GLP-1R internalization in this assay. This measures receptor location, rather than cAMP production. [7]
Retatrutide — Li et al.; engineered cells expressing the glucagon receptor.
- What was compared?
- Changing one amino acid in the receptor (E362A), versus the unaltered receptor.
- What was observed?
- The alteration reduced retatrutide’s cAMP potency. The receptor changed; the peptide remained the same. [4]
Does targeting more receptors mean a stronger response?
No. Receptor count tells you which targets a molecule can activate. It does not tell you the concentration needed to produce a response, how high that response reaches or how long it lasts. Those require measurements at each receptor. [8]
Keep three terms separate: affinity describes binding; potency describes the concentration needed for a response; maximum response describes how high the measured signal reaches. A lower half-maximal effective concentration (EC50) indicates greater potency within an assay, without necessarily indicating a larger maximum. [8]
Before comparing results at GLP-1R, check the receptor system, measured response, exposure time and medium—including albumin. Receptor abundance and signal amplification can influence potency. A finding at GLP-1R also leaves unanswered questions about activity at GIPR or GCGR. [8]
Why two curves reaching 100% may not be equivalent
An experiment may scale its signal to the response produced by a reference compound. If two papers use different references or conditions, 100% can represent different absolute signals. Check each figure’s axes, reference and normalization before comparing the curves. [8]
Write the conclusion in terms of the experiment: name the receptor, cell model, comparator and measured response. That makes clear what the result supports and what still needs testing.
Find original papers and check whether their results are comparable →
Where to go next
For a closer look at one molecule, choose its guide below. Each connects the chemical structure to a specific laboratory experiment you can examine in the original paper.
The molecular and laboratory findings discussed here do not establish effects in people or verify the identity, purity, composition or biological activity of a particular Freedom Peptides lot.
References
- ChEBI — semaglutide (CHEBI:167574)
- KEGG — Tirzepatide (D11360)
- KEGG — Retatrutide (D12430)
- Li et al. (2024) — Structural insights into the triple agonism at GLP-1R, GIPR and GCGR manifested by retatrutide
- Sun et al. (2022) — Structural determinants of dual incretin receptor agonism by tirzepatide
- Lau et al. (2015) — Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide
- Willard et al. (2020) — Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist
- Sum et al. (2019), Assay Guidance Manual — Pharmacological Characterization of GPCR Agonists, Antagonists, Allosteric Modulators and Biased Ligands from HTS Hits to Lead Optimization
- OpenStax, Biology 2e — 9.2 Propagation of the Signal
For laboratory research education only. Not for human consumption, dosing or treatment guidance.
← Back to Research Library